Resveratrol appears to triple the rate of age-related brain shrinkage.
Resveratrol Tested for Alzheimer’s, Arthritis, and Osteoporosis
4.7/5 - (69 votes)
Below is an approximation of this video’s audio content. To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video.
Does resveratrol help with inflammation? In humans, the evidence of an anti-inflammatory effect is sparse and conflicting. About half of the studies show a modest anti-inflammatory effect, but the other half failed to find any. The proof, however, is in the pudding. What about clinical effects on inflammatory disease?
In rats and mice, resveratrol can help ameliorate the effects of experimentally-induced periodontitis, the inflammatory gum disease. However, it appears to have no effect on the progression of chronic periodontitis in human sufferers. Resveratrol may help with the inflammatory bowel disease ulcerative colitis, though. A pilot study of 500 mg a day of resveratrol for six weeks resulted in significantly decreased disease activity and elevated quality of life compared to placebo.
What about inflammatory joint diseases? One pilot study of 500 mg a day of resveratrol for knee osteoarthritis found a decrease in pain within a month, but there was no control group. So, the change can’t really be attributed to starting the supplements.
However, a second pilot study, a randomized, double-blind, placebo-controlled trial, found that the same dose taken as an “add on” to an anti-inflammatory drug significantly improved pain and function within a month in mild-to-moderate knee osteoarthritis sufferers––more than adding a placebo. The one clinical study of rheumatoid arthritis had a control group but no placebo, though there were objective signs of improvement in disease activity after taking 1,000 mg a day for three months.
Resveratrol may also be beneficial to combat menopausal symptoms. Resveratrol has some estrogenic activity. Although it doesn’t appear to help with hormonal migraines, it does appear to help with a couple symptoms of PCOS, polycystic ovary syndrome. RESHAW—Resveratrol for Healthy Ageing in Women—is the longest study of effects of resveratrol supplementation in postmenopausal women. Those randomized to 75 mg of resveratrol twice a day suffered significantly fewer physical menopausal symptoms, including aches and pains, and a general improvement in overall well-being compared to placebo.
The RESHAW study also looked at bone loss prevention. Unfortunately, though animal studies show protective effects on bone tissue, a meta-analysis of human studies on resveratrol supplementation to improve bone quality found no significant effect on bone health markers or bone mineral density of the spine, hip, or overall skeleton. A similar story was found for cognitive effects.
Most studies on resveratrol for brain function in animal models show positive outcomes, but meta-analyses of human studies show no significant effect on memory, processing speed, executive function, or global cognitive performance, which led reviewers to suggest that resveratrol may be a “cognitive enhancer for mice only.” Most human cognition studies found no effect or mixed results—higher performance on some tasks, but lower performance on others, compared to placebo, resulting in a “lack of interpretable cognitive effects.”
Some have suggested the discrepancy between the animal models and the clinical data is that the rodents were massively dosed––up to a gram per kilogram of body weight a day, which would be like giving people an entire bottle of high-dose resveratrol supplements at once. Or, ironically, it could be the opposite, where the doses researchers gave people were too large. A dose-response study found that human cerebral blood flow was maximally boosted by the lowest dose of resveratrol tested––75 mg a day. So, when the RESHAW study was developed, that was the dose they used, given twice a day.
RESHAW was primarily designed to test the effects of resveratrol on cognitive performance. Interim analyses at 14 weeks and a year looked promising, leading the researchers to conclude that their findings “support the adoption of resveratrol as a low-cost, effective intervention to help counteract the age- and menopause-related accelerated cognitive decline in our ageing population.” However, by the end of the two-year study, it’s not clear if the apparent benefit in overall cognition survives adjustment for multiple comparisons––meaning there were so many cognitive outcomes tested that the few treatment differences may well have arisen through chance.
What about cognitive benefit for those who really need it? Observational studies find wine drinkers tend to get less dementia, but it’s hard to disentangle the social, cognitive, and personality factors that accompany a wine-drinking habit. So, researchers decided to put resveratrol to the test for Alzheimer’s disease.
A randomized double-blind, placebo-controlled pilot out of Cornell in 2006 kicked things off with a bang. Patients with mild-to-moderate Alzheimer’s disease who were randomized to a 5 mg resveratrol concoction twice a day ended up with significantly better cognition after three months compared to placebo. There was a greater than expected deterioration in the placebo group, though, suggesting this may have just been a fluke––especially since an attempt to replicate the study with the same dose for a year failed to find any effects of statistical significance. Maybe the researchers just didn’t use a high enough dose?
More than a hundred patients with mild to moderate Alzheimer’s were randomized to placebo or an escalating dose of resveratrol starting at a hundred times the dose of the previous study—500 mg once a day and ending at a 1,000 mg twice a day. After a year, there were no significant improvements in cognition or the performance of activities of daily living compared to placebo. Instead, there was a significant acceleration of brain volume loss. At the end of the study, there was triple the brain volume loss (3 percent versus 1 percent) in the resveratrol group. And the only other randomized, double-blind, placebo-controlled trial to date found the same thing: no significant cognitive benefits and the same tripling of age-related brain shrinkage. The authors tried to somehow spin this as a positive, like hey—maybe that’s just decreased brain swelling, but as a team of researchers wrote in an understatement of the year, “It is difficult to reconcile these effects as potentially beneficial.”
Please consider volunteering to help out on the site.
- Poulsen MM, Fjeldborg K, Ornstrup MJ, Kjær TN, Nøhr MK, Pedersen SB. Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes. Biochim Biophys Acta. 2015;1852(6):1124-1136.
- Bhattarai G, Poudel SB, Kook SH, Lee JC. Resveratrol prevents alveolar bone loss in an experimental rat model of periodontitis. Acta Biomater. 2016;29:398-408.
- Zhen L, Fan DS, Zhang Y, Cao XM, Wang LM. Resveratrol ameliorates experimental periodontitis in diabetic mice through negative regulation of TLR4 signaling. Acta Pharmacol Sin. 2015;36(2):221-228.
- Javid AZ, Hormoznejad R, Yousefimanesh HA, Haghighi-Zadeh MH, Zakerkish M. Impact of resveratrol supplementation on inflammatory, antioxidant, and periodontal markers in type 2 diabetic patients with chronic periodontitis. Diabetes Metab Syndr. 2019;13(4):2769-2774.
- Samsamikor M, Daryani NE, Asl PR, Hekmatdoost A. Resveratrol supplementation and oxidative/anti-oxidative status in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. Arch Med Res. 2016;47(4):304-309.
- Marouf BH. Effect of resveratrol on serum levels of type II collagen and aggrecan in patients with knee osteoarthritis: a pilot clinical study. Biomed Res Int. 2021;2021:3668568.
- Hussain SA, Marouf BH, Ali ZS, Ahmmad RS. Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study. Clin Interv Aging. 2018;13:1621-1630.
- Khojah HM, Ahmed S, Abdel-Rahman MS, Elhakeim EH. Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study. Clin Rheumatol. 2018;37(8):2035-2042.
- Qasem RJ. The estrogenic activity of resveratrol: a comprehensive review of in vitro and in vivo evidence and the potential for endocrine disruption. Crit Rev Toxicol. 2020;50(5):439-462.
- Dzator JSA, Howe PRC, Coupland KG, Wong RHX. A randomised, double-blind, placebo-controlled crossover trial of resveratrol supplementation for prophylaxis of hormonal migraine. Nutrients. 2022;14(9):1763.
- Mansour A, Samadi M, Sanginabadi M, et al. Effect of resveratrol on menstrual cyclicity, hyperandrogenism and metabolic profile in women with PCOS. Clin Nutr. 2021;40(6):4106-4112.
- Wong RH, Thaung Zaw JJ, Xian CJ, Howe PR. Regular supplementation with resveratrol improves bone mineral density in postmenopausal women: a randomized, placebo-controlled trial. J Bone Miner Res. 2020;35(11):2121-2131.
- Thaung Zaw JJ, Howe PRC, Wong RHX. Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial. Menopause. 2020;28(1):40-49.
- Li Q, Yang G, Xu H, Tang S, Lee WYW. Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Med Ther. 2021;21(1):214.
- Khorshidi F, Poljak A, Liu Y, Lo JW, Crawford JD, Sachdev PS. Resveratrol: A “miracle” drug in neuropsychiatry or a cognitive enhancer for mice only? A systematic review and meta-analysis. Ageing Res Rev. 2021;65:101199.
- Marx W, Kelly JT, Marshall S, et al. Effect of resveratrol supplementation on cognitive performance and mood in adults: a systematic literature review and meta-analysis of randomized controlled trials. Nutr Rev. 2018;76(6):432-443.
- Wightman EL, Haskell-Ramsay CF, Reay JL, et al. The effects of chronic trans-resveratrol supplementation on aspects of cognitive function, mood, sleep, health and cerebral blood flow in healthy, young humans. Br J Nutr. 2015;114(9):1427-1437.
- Porquet D, Casadesús G, Bayod S, et al. Dietary resveratrol prevents Alzheimer’s markers and increases life span in SAMP8. Age (Dordr). 2013;35(5):1851-1865.
- Wong RHX, Nealon RS, Scholey A, Howe PRC. Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2016;26(5):393-399.
- Evans HM, Howe PRC, Wong RHX. Effects of resveratrol on cognitive performance, mood and cerebrovascular function in post-menopausal women; a 14-week randomised placebo-controlled intervention trial. Nutrients. 2017;9(1):27.
- Thaung Zaw JJ, Howe PRC, Wong RHX. Sustained cerebrovascular and cognitive benefits of resveratrol in postmenopausal women. Nutrients. 2020;12(3):828.
- Thaung Zaw JJ, Howe PR, Wong RH. Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study. Clin Nutr. 2021;40(3):820-829.
- Tosatti JAG, Fontes AF da S, Caramelli P, Gomes KB. Effects of resveratrol supplementation on the cognitive function of patients with alzheimer’s disease: a systematic review of randomized controlled trials. Drugs Aging. 2022;39(4):285-295.
- Mehlig K, Skoog I, Guo X, et al. Alcoholic beverages and incidence of dementia: 34-year follow-up of the prospective population study of women in Goteborg. Am J Epidemiol. 2008;167(6):684-691.
- Rabassa M, Zamora-Ros R, Urpi-Sarda M, et al. Association of habitual dietary resveratrol exposure with the development of frailty in older age: the Invecchiare in Chianti study. Am J Clin Nutr. 2015;102(6):1534-1542.
- Blass JP, Gibson GE. Correlations of disability and biologic alterations in Alzheimer brain and test of significance by a therapeutic trial in humans. J Alzheimers Dis. 2006;9(2):207-218.
- Zhu CW, Grossman H, Neugroschl J, et al. A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (Rgm) to slow the progression of Alzheimer’s disease: A pilot study. Alzheimers Dement (N Y). 2018;4:609-616.
- Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85(16):1383-1391.
- Gu J, Li Z, Chen H, Xu X, Li Y, Gui Y. Neuroprotective effect of trans-resveratrol in mild to moderate Alzheimer disease: a randomized, double-blind trial. Neurol Ther. 2021;10(2):905-917.
- Moussa C, Hebron M, Huang X, et al. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J Neuroinflammation. 2017;14(1):1.
Motion graphics by Avo Media
Below is an approximation of this video’s audio content. To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video.
Does resveratrol help with inflammation? In humans, the evidence of an anti-inflammatory effect is sparse and conflicting. About half of the studies show a modest anti-inflammatory effect, but the other half failed to find any. The proof, however, is in the pudding. What about clinical effects on inflammatory disease?
In rats and mice, resveratrol can help ameliorate the effects of experimentally-induced periodontitis, the inflammatory gum disease. However, it appears to have no effect on the progression of chronic periodontitis in human sufferers. Resveratrol may help with the inflammatory bowel disease ulcerative colitis, though. A pilot study of 500 mg a day of resveratrol for six weeks resulted in significantly decreased disease activity and elevated quality of life compared to placebo.
What about inflammatory joint diseases? One pilot study of 500 mg a day of resveratrol for knee osteoarthritis found a decrease in pain within a month, but there was no control group. So, the change can’t really be attributed to starting the supplements.
However, a second pilot study, a randomized, double-blind, placebo-controlled trial, found that the same dose taken as an “add on” to an anti-inflammatory drug significantly improved pain and function within a month in mild-to-moderate knee osteoarthritis sufferers––more than adding a placebo. The one clinical study of rheumatoid arthritis had a control group but no placebo, though there were objective signs of improvement in disease activity after taking 1,000 mg a day for three months.
Resveratrol may also be beneficial to combat menopausal symptoms. Resveratrol has some estrogenic activity. Although it doesn’t appear to help with hormonal migraines, it does appear to help with a couple symptoms of PCOS, polycystic ovary syndrome. RESHAW—Resveratrol for Healthy Ageing in Women—is the longest study of effects of resveratrol supplementation in postmenopausal women. Those randomized to 75 mg of resveratrol twice a day suffered significantly fewer physical menopausal symptoms, including aches and pains, and a general improvement in overall well-being compared to placebo.
The RESHAW study also looked at bone loss prevention. Unfortunately, though animal studies show protective effects on bone tissue, a meta-analysis of human studies on resveratrol supplementation to improve bone quality found no significant effect on bone health markers or bone mineral density of the spine, hip, or overall skeleton. A similar story was found for cognitive effects.
Most studies on resveratrol for brain function in animal models show positive outcomes, but meta-analyses of human studies show no significant effect on memory, processing speed, executive function, or global cognitive performance, which led reviewers to suggest that resveratrol may be a “cognitive enhancer for mice only.” Most human cognition studies found no effect or mixed results—higher performance on some tasks, but lower performance on others, compared to placebo, resulting in a “lack of interpretable cognitive effects.”
Some have suggested the discrepancy between the animal models and the clinical data is that the rodents were massively dosed––up to a gram per kilogram of body weight a day, which would be like giving people an entire bottle of high-dose resveratrol supplements at once. Or, ironically, it could be the opposite, where the doses researchers gave people were too large. A dose-response study found that human cerebral blood flow was maximally boosted by the lowest dose of resveratrol tested––75 mg a day. So, when the RESHAW study was developed, that was the dose they used, given twice a day.
RESHAW was primarily designed to test the effects of resveratrol on cognitive performance. Interim analyses at 14 weeks and a year looked promising, leading the researchers to conclude that their findings “support the adoption of resveratrol as a low-cost, effective intervention to help counteract the age- and menopause-related accelerated cognitive decline in our ageing population.” However, by the end of the two-year study, it’s not clear if the apparent benefit in overall cognition survives adjustment for multiple comparisons––meaning there were so many cognitive outcomes tested that the few treatment differences may well have arisen through chance.
What about cognitive benefit for those who really need it? Observational studies find wine drinkers tend to get less dementia, but it’s hard to disentangle the social, cognitive, and personality factors that accompany a wine-drinking habit. So, researchers decided to put resveratrol to the test for Alzheimer’s disease.
A randomized double-blind, placebo-controlled pilot out of Cornell in 2006 kicked things off with a bang. Patients with mild-to-moderate Alzheimer’s disease who were randomized to a 5 mg resveratrol concoction twice a day ended up with significantly better cognition after three months compared to placebo. There was a greater than expected deterioration in the placebo group, though, suggesting this may have just been a fluke––especially since an attempt to replicate the study with the same dose for a year failed to find any effects of statistical significance. Maybe the researchers just didn’t use a high enough dose?
More than a hundred patients with mild to moderate Alzheimer’s were randomized to placebo or an escalating dose of resveratrol starting at a hundred times the dose of the previous study—500 mg once a day and ending at a 1,000 mg twice a day. After a year, there were no significant improvements in cognition or the performance of activities of daily living compared to placebo. Instead, there was a significant acceleration of brain volume loss. At the end of the study, there was triple the brain volume loss (3 percent versus 1 percent) in the resveratrol group. And the only other randomized, double-blind, placebo-controlled trial to date found the same thing: no significant cognitive benefits and the same tripling of age-related brain shrinkage. The authors tried to somehow spin this as a positive, like hey—maybe that’s just decreased brain swelling, but as a team of researchers wrote in an understatement of the year, “It is difficult to reconcile these effects as potentially beneficial.”
Please consider volunteering to help out on the site.
- Poulsen MM, Fjeldborg K, Ornstrup MJ, Kjær TN, Nøhr MK, Pedersen SB. Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes. Biochim Biophys Acta. 2015;1852(6):1124-1136.
- Bhattarai G, Poudel SB, Kook SH, Lee JC. Resveratrol prevents alveolar bone loss in an experimental rat model of periodontitis. Acta Biomater. 2016;29:398-408.
- Zhen L, Fan DS, Zhang Y, Cao XM, Wang LM. Resveratrol ameliorates experimental periodontitis in diabetic mice through negative regulation of TLR4 signaling. Acta Pharmacol Sin. 2015;36(2):221-228.
- Javid AZ, Hormoznejad R, Yousefimanesh HA, Haghighi-Zadeh MH, Zakerkish M. Impact of resveratrol supplementation on inflammatory, antioxidant, and periodontal markers in type 2 diabetic patients with chronic periodontitis. Diabetes Metab Syndr. 2019;13(4):2769-2774.
- Samsamikor M, Daryani NE, Asl PR, Hekmatdoost A. Resveratrol supplementation and oxidative/anti-oxidative status in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. Arch Med Res. 2016;47(4):304-309.
- Marouf BH. Effect of resveratrol on serum levels of type II collagen and aggrecan in patients with knee osteoarthritis: a pilot clinical study. Biomed Res Int. 2021;2021:3668568.
- Hussain SA, Marouf BH, Ali ZS, Ahmmad RS. Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study. Clin Interv Aging. 2018;13:1621-1630.
- Khojah HM, Ahmed S, Abdel-Rahman MS, Elhakeim EH. Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study. Clin Rheumatol. 2018;37(8):2035-2042.
- Qasem RJ. The estrogenic activity of resveratrol: a comprehensive review of in vitro and in vivo evidence and the potential for endocrine disruption. Crit Rev Toxicol. 2020;50(5):439-462.
- Dzator JSA, Howe PRC, Coupland KG, Wong RHX. A randomised, double-blind, placebo-controlled crossover trial of resveratrol supplementation for prophylaxis of hormonal migraine. Nutrients. 2022;14(9):1763.
- Mansour A, Samadi M, Sanginabadi M, et al. Effect of resveratrol on menstrual cyclicity, hyperandrogenism and metabolic profile in women with PCOS. Clin Nutr. 2021;40(6):4106-4112.
- Wong RH, Thaung Zaw JJ, Xian CJ, Howe PR. Regular supplementation with resveratrol improves bone mineral density in postmenopausal women: a randomized, placebo-controlled trial. J Bone Miner Res. 2020;35(11):2121-2131.
- Thaung Zaw JJ, Howe PRC, Wong RHX. Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial. Menopause. 2020;28(1):40-49.
- Li Q, Yang G, Xu H, Tang S, Lee WYW. Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Med Ther. 2021;21(1):214.
- Khorshidi F, Poljak A, Liu Y, Lo JW, Crawford JD, Sachdev PS. Resveratrol: A “miracle” drug in neuropsychiatry or a cognitive enhancer for mice only? A systematic review and meta-analysis. Ageing Res Rev. 2021;65:101199.
- Marx W, Kelly JT, Marshall S, et al. Effect of resveratrol supplementation on cognitive performance and mood in adults: a systematic literature review and meta-analysis of randomized controlled trials. Nutr Rev. 2018;76(6):432-443.
- Wightman EL, Haskell-Ramsay CF, Reay JL, et al. The effects of chronic trans-resveratrol supplementation on aspects of cognitive function, mood, sleep, health and cerebral blood flow in healthy, young humans. Br J Nutr. 2015;114(9):1427-1437.
- Porquet D, Casadesús G, Bayod S, et al. Dietary resveratrol prevents Alzheimer’s markers and increases life span in SAMP8. Age (Dordr). 2013;35(5):1851-1865.
- Wong RHX, Nealon RS, Scholey A, Howe PRC. Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2016;26(5):393-399.
- Evans HM, Howe PRC, Wong RHX. Effects of resveratrol on cognitive performance, mood and cerebrovascular function in post-menopausal women; a 14-week randomised placebo-controlled intervention trial. Nutrients. 2017;9(1):27.
- Thaung Zaw JJ, Howe PRC, Wong RHX. Sustained cerebrovascular and cognitive benefits of resveratrol in postmenopausal women. Nutrients. 2020;12(3):828.
- Thaung Zaw JJ, Howe PR, Wong RH. Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study. Clin Nutr. 2021;40(3):820-829.
- Tosatti JAG, Fontes AF da S, Caramelli P, Gomes KB. Effects of resveratrol supplementation on the cognitive function of patients with alzheimer’s disease: a systematic review of randomized controlled trials. Drugs Aging. 2022;39(4):285-295.
- Mehlig K, Skoog I, Guo X, et al. Alcoholic beverages and incidence of dementia: 34-year follow-up of the prospective population study of women in Goteborg. Am J Epidemiol. 2008;167(6):684-691.
- Rabassa M, Zamora-Ros R, Urpi-Sarda M, et al. Association of habitual dietary resveratrol exposure with the development of frailty in older age: the Invecchiare in Chianti study. Am J Clin Nutr. 2015;102(6):1534-1542.
- Blass JP, Gibson GE. Correlations of disability and biologic alterations in Alzheimer brain and test of significance by a therapeutic trial in humans. J Alzheimers Dis. 2006;9(2):207-218.
- Zhu CW, Grossman H, Neugroschl J, et al. A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (Rgm) to slow the progression of Alzheimer’s disease: A pilot study. Alzheimers Dement (N Y). 2018;4:609-616.
- Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85(16):1383-1391.
- Gu J, Li Z, Chen H, Xu X, Li Y, Gui Y. Neuroprotective effect of trans-resveratrol in mild to moderate Alzheimer disease: a randomized, double-blind trial. Neurol Ther. 2021;10(2):905-917.
- Moussa C, Hebron M, Huang X, et al. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J Neuroinflammation. 2017;14(1):1.
Motion graphics by Avo Media
Republishing "Resveratrol Tested for Alzheimer’s, Arthritis, and Osteoporosis"
Terms
You may republish this material online or in print under our Creative Commons licence. You must attribute the article to NutritionFacts.org with a link back to our website in your republication.
If any changes are made to the original text or video, you must indicate, reasonably, what has changed about the article or video.
You may not use our material for commercial purposes.
You may not apply legal terms or technological measures that restrict others from doing anything permitted here.
If you have any questions, please Contact Us
Title
Resveratrol Tested for Alzheimer’s, Arthritis, and Osteoporosis
LicenseCreative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Content URLDoctor's Note
This is the third video in a four-part series on resveratrol. If you missed either of the first two, see Does Resveratrol Make You Live Longer? and Does Resveratrol Benefit Our Metabolic Health?.
The last video is coming up: Side Effects of Resveratrol Supplements. (As if a tripling in brain shrinkage wasn’t bad enough!)
What is The Best Exercise Type and Frequency for Bone Density? Check out the video.
What are the Benefits and Side Effects of Glucosamine for Osteoarthritis and the Benefits and Side Effects of Chondroitin for Osteoarthritis? Check out the videos.
I’ve got a lot of other videos on Alzheimer’s disease, arthritis, and osteoporosis that you can explore.
If you haven't yet, you can subscribe to our free newsletter. With your subscription, you'll also get notifications for just-released blogs and videos. Check out our information page about our translated resources.
Previous Video
Next Video
